Evidence map›Paper›PMID 32894310›Full record

ReviewDiabetologia2020

Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?

Roberto Mallone, Decio L Eizirik

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. How loss-of-function mutations inJournal of translational autoimmunity · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 3 countries.

Roberto MalloneUniversité de Paris, Institut Cochin, CNRS, INSERM, G.H. Cochin-Port Royal, Cassini building, 123 boulevard de Port Royal, 75014, Paris, France. roberto.mallone@inserm.fr.ORCID 0000-0002-9846-8861
Decio L EizirikULB Center for Diabetes Research and WELBIO, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID 0000-0003-2453-5889
Centre National de la Recherche Scientifique · FRUniversité Libre de Bruxelles · BE

Funding

Agence Nationale de la Recherche ANR-19-CE15-0014-01EU IMI2 115797Fondation pour la Recherche Médicale EQU20193007831Innovative Medicines Initiative 2 945268Juvenile Diabetes Research Foundation 2-SRA-2016-164-Q-RThe Leona M. and Harry B. Helmsley Charitable Trust 1901-03689Welbio/FRFS WELBIO-CR-2019C-04
6 · The paper itself

Abstract

It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue within and possibly outside the pancreas. Indeed, autoimmune CD8

Indexed as

AutoimmunityCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseHumansInflammationInsulinInsulin-Secreting CellsInsulin SecretionProinsulinSecretory VesiclesUnfolded Protein ResponseInsulinProinsulinAntigenAutoimmunityBenignCoxsackievirusEndotypeEpitopeIsletProinsulinReviewT cell

Identifiers

PMID32894310
OpenAlexW3083835927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.